Clinicopathological features of salivary and non-salivary adenoid cystic carcinomas.
Adenoid cystic carcinoma (ACC), commonly from salivary glands, is known for its insidious local growth and usually protracted clinical course. ACC developing from non-salivary glands (i.e., non-salivary ACC) is heterogeneous, and its clinicopathological features remain poorly defined. Patients treated for ACC in a single institution between 1995 and 2007 were included in this study. Immunohistochemical evaluation of Ki-67, E-cadherin, p16, and cyclinD1 was performed. The prognostic significance of clinical and immunophenotypic markers was evaluated. 83 cases of salivary ACC and 24 cases of non-salivary ACC were included. The expression levels of Ki-67 (54.8%), E-cadherin (90.4%), p16 (32.9%), and cyclinD1 (19.2%) between ACCs present at various sites were not different. Sinonasal, lacrimal, and tracheobronchial ACCs had significantly worse outcomes than those of ACC of the major salivary glands. Postoperative radiotherapy reduced the recurrence rate of patients with a negative resection margin (P=0.028). Older age (age >60 years), advanced stage, positive resection margin, high histological grade, and high expression of Ki-67 were significantly correlated with poor prognosis. In conclusion, the site of origin plays a role in the prognosis of ACC, in which positive resection margin and advanced stage are possible factors underlying the differences in outcomes.
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Yu-Chin
YC
Lin
Ko-Chin
KC
Chen
Ching-Hung
CH
Lin
Kuan-Ting
KT
Kuo
Jeng-Yuh
JY
Ko
Ruey-Long
RL
Hong
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001984:Bronchial Neoplasms / Q000473:pathology / Q000601:surgery; D015820:Cadherins / Q000032:analysis; D003528:Carcinoma, Adenoid Cystic / Q000473:pathology* / Q000601:surgery; D019938:Cyclin D1 / Q000032:analysis; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D007766:Lacrimal Apparatus Diseases / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000473:pathology / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D014134:Tracheal Neoplasms / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D055815:Young Adult
C530104:CCND1 protein, human; D015820:Cadherins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen; D019938:Cyclin D1